CBD Product Case Reports: Why the Label Cannot Resolve a THC Result
Five emergency presentations after products described as CBD illustrate why product identity, specimen type and analytical timing need separate review. The case series does not prove that pure CBD converted into THC inside the patients.
The records were not uniform
The Japanese series described five patients with symptoms after CBD-labeled products. Product information was available for some cases but not others. Biological testing included a urine screen and, where collected, serum and urine THC-COOH measurements.
Case 1 had no serum or urine specimen collected for the reported metabolite table. In Case 2, the urine screen was negative while serum THC-COOH was detected. These details should not be collapsed into a claim that every patient had identical confirmatory findings.
Product claims and laboratory evidence differ
The paper discussed multiple cannabinoids and analogs in available product information. A product marketed as ‘CBD’ is not analytically established to contain only CBD. Conversely, symptoms such as vomiting are not specific chemical identifiers.
Two patients reporting use of the same e-cigarette had different screening results. Their histories, timing and biological findings require individual consideration rather than assuming a shared product must produce matching tests.
A conversion hypothesis was not demonstrated
A positive metabolite finding does not determine whether exposure came from undeclared THC, prior use, product transformation or another explanation. The authors discussed possible conversion, but the case records did not experimentally establish conversion of pure CBD inside a human body.
A small uncontrolled series cannot estimate how frequently these events occur among all CBD users. It also cannot establish a universal retesting interval or impairment threshold. The practical contribution is to preserve the actual product evidence, collection history, matrix and confirmation results without turning an incomplete record into a definitive causal explanation.
Related analysis
See our analysis of why a chemical result does not determine functional impairment.
Primary research
Yukari Maki and colleagues. Safety of cannabidiol products as a social issue: A case series. Acute Medicine & Surgery, 2024. DOI: 10.1002/ams2.965.
